Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study.

Blood Adv · 2025 · PMC12051115 · PMID 39787607

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

of borderline significanceP = .094so close (0.05 < p ≤ 0.1)

Although the improvement in toxicity was of borderline significance (median values of NCI-PRO-CTCAE scores on- and off-treatment 19 [IQR, 15.5-22.5] and 10 [IQR, 7.5-17]; P = .094), most patients (n = 8, 72%) reported an improvement in therapy-related side effects during off-therapy according to the NCI-PRO-CTCAE.

also in 469 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.